ASCO 2021

Researchers sought to determine whether daratumumab maintenance therapy would be effective in patients with newly diagnosed multiple myeloma.

Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.

Researchers sought to determine whether a combination carfilzomib-lenalidomide-dexamethasone induction and consolidation with ASCT would improve survival in patients with MM with cytogenetic abnormalities.

Researchers sought to determine whether carfilzomib-based consolidation and maintenance therapy regimen may yield similar outcomes to those seen with ASCT in patients with MM.

Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.

Researchers sought to determine whether myeloablative consolidation after induction therapy would improve PFS in patients with newly diagnosed primary central nervous system lymphoma.

The following article features coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to read more of MPR‘s conference coverage. Among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), fixed-duration, first-line treatment with ibrutinib and venetoclax appears to induce both deep and durable responses, according to research presented at…

Researchers are conducting a randomized phase 3 trial evaluating the safety and efficacy of venetoclax with azacitidine among patients with previously untreated, higher-risk MDS.

Researchers sought to determine whether C-CAR039 would be safe and effective in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.